0001104659-19-065857.txt : 20191120
0001104659-19-065857.hdr.sgml : 20191120
20191120161548
ACCESSION NUMBER: 0001104659-19-065857
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191119
FILED AS OF DATE: 20191120
DATE AS OF CHANGE: 20191120
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Aghazadeh Behzad
CENTRAL INDEX KEY: 0001701815
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-12104
FILM NUMBER: 191234412
MAIL ADDRESS:
STREET 1: C/O AVORO CAPITAL ADVISORS LLC
STREET 2: 110 GREENE STREET, SUITE 800
CITY: NEW YORK
STATE: NY
ZIP: 10012
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Avoro Capital Advisors LLC
CENTRAL INDEX KEY: 0001633313
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-12104
FILM NUMBER: 191234413
BUSINESS ADDRESS:
STREET 1: 110 GREENE STREET
STREET 2: SUITE 800
CITY: NEW YORK
STATE: NY
ZIP: 10012
BUSINESS PHONE: 212-937-4975
MAIL ADDRESS:
STREET 1: 110 GREENE STREET
STREET 2: SUITE 800
CITY: NEW YORK
STATE: NY
ZIP: 10012
FORMER NAME:
FORMER CONFORMED NAME: venBio Select Advisor LLC
DATE OF NAME CHANGE: 20150210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IMMUNOMEDICS INC
CENTRAL INDEX KEY: 0000722830
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 611009366
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 AMERICAN RD
CITY: MORRIS PLAINS
STATE: NJ
ZIP: 07950
BUSINESS PHONE: 9736058200
MAIL ADDRESS:
STREET 1: 300 AMERICAN ROAD
CITY: MORRIS PLAINS
STATE: NJ
ZIP: 07950
4
1
a4.xml
4
X0306
4
2019-11-19
0
0000722830
IMMUNOMEDICS INC
IMMU
0001701815
Aghazadeh Behzad
C/O AVORO CAPITAL ADVISORS LLC
110 GREENE STREET, SUITE 800
NEW YORK
NY
10012
1
0
1
1
See Remarks
0001633313
Avoro Capital Advisors LLC
C/O AVORO CAPITAL ADVISORS LLC
110 GREENE STREET, SUITE 800
NEW YORK
NY
10012
1
0
1
1
See Remarks
Stock Option (right to buy)
18.74
2019-11-19
4
A
0
150000
0
A
2026-11-19
Common Stock, par value $0.01 per share
150000
150000
D
Dr. Aghazadeh was granted stock options pursuant to the Issuer's 2014 Long-Term Incentive Plan. 50,000 of the stock options vest upon the U.S. Food and Drug Administration's ("FDA") acceptance of the resubmission of the Issuer's Biologics License Application for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease under the Prescription Drug User Fee Act (the "BLA"), and 100,000 of the stock options vest upon the Issuer's receipt of approval from the FDA for the BLA.
Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors LLC (formerly venBio Select Advisor LLC), a Delaware limited liability company (the "Investment Manager"). The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
The Investment Manager may be deemed a director by deputization of Immunomedics, Inc. (the "Issuer") by virtue of the fact that Dr. Aghazadeh currently serves on the board of directors of the Issuer.
/s/ Behzad Aghazadeh
2019-11-19
Avoro Capital Advisors LLC, by: /s/ Behzad Aghazadeh, authorized signatory
2019-11-19